Recombinant Norovirus bivalent (GI.1/GII.4) vaccine (Lanzhou institute of biological products)

重组诺如病毒双价（GⅠ.1/GⅡ.4）疫苗（兰州生物制品研究所）

Report date: 2023/05/30 20:00:25

Base Information

Drug NameRecombinant Norovirus bivalent (GI.1/GII.4) vaccine (Lanzhou institute of biological products)
Drug Alias Name重组诺如病毒双价(GⅠ.1/GⅡ.4)疫苗（兰州生物制品研究所）
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsNorwalk virus infectionsNorovirus InfectionsGastroenteritis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLanzhou Institute Of Biological Products Co LtdChina National Biotec Group Co LtdBeijing Institute Of Biological Products Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNational Vaccine and Serum Institute, ChinaLanzhou Institute Of Biological Products Co LtdBeijing Institute Of Biological Products Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsNorwalk virus infectionsNorovirus InfectionsGastroenteritis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A